linagliptin glp 1 PDB-101: Diabetes Mellitus: Diabetes Mellitus: undefined: GLP-1 Type 1 Adjunct Therapy:

Animal Model:Leptin receptor knockout (db/db) mice, a model of DM2 [4] Dosage:50 mg/kg , daily, 6 weeks Administration:Oral gavage (p.o.) Result:Eliminated endothelial dysfunction in the arteries of db/db mice, increased endothelial nitric oxide synthase (eNOS) phosphorylation (Ser1177), increased the expression of superoxide dismutase-1 and catalase in the arteries of db/db mice, improved relaxation induced by sodium nitroprusside and BAY 41-2277, and increased the expression of soluble corona yl cyclase (sGC) subunit

One diner asked for soup with sliced chunks of steak, and another asked for smaller portions of existing dishes

Is Ozempic for athletes a performance tool or a nutritional red flag

Acetate mediates a microbiome-brain--cell axis to promote metabolic syndrome